The blockbuster diabetes product: long-acting GLP-1 receptor agonist polyethylene glycol loxenatide (trade name: Fulaimei) of Hansoh Pharmaceutical has been marketed on May 7, 2019, which is indicated for type 2 diabetes and administered once every week. Polyethylene glycol loxenatide is the 3rd long-acting GLP-1 receptor agonist approved for marketing in China following exenatide microspheres (trade name: Bydureon) of AstraZeneca/3SBio and dulaglutide (trade name: Trulicity) of Eli Lilly.
In the diabetes business of Hansoh at present, the first generic variety: Fulaidi (repaglinide) is its core product and also the first generic drug of repaglinide tablets that has passed the consistency evaluation in China, with the market share of about 22.7% in China; the marketing of the polyethylene glycol loxenatide independently developed by it will significantly optimize Hansoh’s diabetes business and bring a long-term driving force to its performance growth!
This article will focus on the long-acting mechanism of GLP-1R agonists and the global GLP-1 receptor agonist market and introduce the market performance of the major GLP-1 receptor agonists!
I. Hansoh Pharmaceutical’s blockbuster innovative diabetes drug: polyethylene glycol loxenatide
There have been mainly 4 GLP-1R agonist drugs approved for marketing in the world so far, separately: Bydureon (exenatide microspheres), Tanzeum (albiglutide), Trulicity (dulaglutide), and Ozempic (semaglutide).
The IND application of polyethylene glycol loxenatide was accepted by CDE in 2007; Phase 3 clinical trial of polyethylene glycol loxenatide was completed by Hansoh in May 2016; the marketing application of the drug was accepted by CDE in Dec. 2017. After nearly 12 years, polyethylene glycol loxenatide is eventually approved for marketing, as a blockbuster diabetes product developed by Hansoh Pharmaceutical.
II. The long-acting mechanism of long-acting GLP-1R agonists
There have been 5 long-acting GLP-1R agonists approved for marketing worldwide so far, separately exenatide microspheres, albiglutide, dulaglutide, semaglutide, and Hansoh Pharmaceutical’s polyethylene glycol loxenatide. This is the result of the joint efforts of many medical surgical supply companies.
Long-acting GLP-1R Agonists Approved for Marketing Worldwide
Trade name | Generic name | Company | Approval time in the U.S. |
Bydureon | Exenatide microspheres | AstraZeneca/3SBio | Jan. 27, 2012 |
Tanzeu | Albiglutide | GSK | Apr. 15, 2014 |
Trulicity | Dulaglutide | Eli Lilly | Sep. 18, 2014 |
Ozempic | Semaglutide | Novo Nordisk | Dec. 5, 2017 |
Fulaimei | Polyethylene glycol loxenatide | Hansoh Pharmaceutical | May 7, 2019 |
Generic name |
David Orchard-Webb
June 23, 2025
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight
E-Compilation! Note: You can unsubscribe from the alerts at any time. Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight
E-Compilation! Note: You can unsubscribe from the alerts at any time. |
![Polyethylene caps for containers of foodstuff[7]Polyethylene caps for containers of foodstuff](https://eimg.pharmasources.com/image/20220715/09JGdpxbvJGaE2g86Y0ihHuoCq0DJe376fkgNgpu.png)
(All Rights Reserved)